More recently, several ICIs are used in clinical trials, especially the programmed cell death protein-1 (PD-1) inhibitors, which block PD-1 or PD-L1 have proven a promising efficacy and safety in treatment of advanced HCC (11, 19). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.